HOME

ERA-EDTA WORKING GROUP ON CHRONIC KIDNEY DISEASE AND MINERAL BONE DISORDER (CKD-MBD)

CKD-MBD News

3th European Renal Osteodystrophy (EUROD) winter meeting

We are pleased to inform you that the 2020 EUROD winter meeting is currently in preparation to outperform all previous years for you! The 2020 edition will take place from January 16 to January 18, 2020 at the historical Convent of Chièvres in Leuven (Belgium).

The meeting will consist of a research forum (January 16),  a CME dedicated to the topic of “Vitamins and oxidative stress on the cross-roads of bone and vessels” and a hands-on CME dealing with the “Challenge of osteoporosis therapy in advanced CKD”.
Faculty (confirmed) includes M. Vervloet, S. Mazzaferro, S. Salam, J. Cunningham, M. Fusaro, L. Schurgers, J. Floege, and P. Stenvinkel.
The EUROD winter meeting is a great opportunity to interact with other delegates specialized in the field in an open and friendly atmosphere.
Travel grants for best abstracts (call to be expected in Sept 2019).
Save the date now! All important information such as the final program or the online registration form will soon be available on the ERA-EDTA website (CKD-MBD working group).
The Symposium Chairman,
Pieter Evenepoel

 


The ERA-EDTA Council recently approved the creation of a working group dedicated to Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). This acronym, or its translation, has been increasingly endorsed by different Nephrology Societies and International initiatives, including both the KDIGO (Kidney Disease Improving Global Outcomes) and the EBPG (European Best Practice Guidelines).

The definition of CKD-MBD is different than the previously recognized as "renal osteodystrophy", and it refers to a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:

  • Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), or vitamin D metabolism.
  • Abnormalities in bone turnover, mineralization, volume, linear growth, or strenght.
  • Vascular or other soft-tissue calcification.

The term "renal osteodystrophy" is now limited to an alteration of bone morphology in patients with CKD, and it is one measure of the skeletal component of the systemic disorder of CKD-MBD that is quantifiable by histomorphometry of bone biopsy.

image 1

 

Thus, the CKD-MBD Working Group becomes an independent scientific organization comprising a group of European academic medical institutions aligned to CKD-MBD regarding:

  • Enhancing the scientific understanding and preclinical background.
  • Analyzing the clinical implications.
  • Elaborating therapeutic options.
Special emphasis is on:
  • Increasing research collaborations.
  • Promote education for Fellows and Faculty.
  • Improve scientific communication and dissemination of knowledge in the field.

HISTORY OF THE GROUP
AIMS

As per the ERA-EDTA regulations for Working groups, the vision and mission of the CKD-MBD Working Group are:

  • To promote and organize pan-European independent research in the field of CKD-MBD including both basic, translational and clinical research.
  • To improve and distribute knowledge in the field of CKD-MBD (appropriate therapies, Guidelines, etc.).
  • To address particular research questions that have not and may not be addressed by usual means.
  • To organize a structured educational process and program for young researchers in the field of CKD-MBD allowing them to start networking and exchange expertise.
  • To collaborate to the organization of educational activities of the ERA-EDTA.
  • To develop training concepts for both clinical as well as research activities throughout Europe.
  • To organize an annual meeting focusing on educational themes and on research proposals.
  • To organize an annual meeting during the annual ERA-EDTA Congress, to be included in the Scientific Program.